All contents

Are antibody tests the key to reassuring staff that it's safe to return to work?

Are antibody tests the key to reassuring staff that it's safe to return to work?

View more 
How to: improve lateral flow test output while focusing on core business activities

How to: improve lateral flow test output while focusing on core business activities

View more 
COVID-19 neutralising antibody tests – an integrated approach

COVID-19 neutralising antibody tests – an integrated approach

View more 
As COVID-19 restrictions lift, antibody testing could today be playing a vital role

As COVID-19 restrictions lift, antibody testing could today be playing a vital role

View more 
How antibody testing can help unlock hard-hit sectors – Live Events

How antibody testing can help unlock hard-hit sectors – Live Events

View more 
Unlocking the education experience for September

Unlocking the education experience for September

View more 
CASE STUDY: Why knowing your COVID-19 antibody status is important

CASE STUDY: Why knowing your COVID-19 antibody status is important

View more 
Designing a robust lateral flow test specification for high-volume manufacture

Designing a robust lateral flow test specification for high-volume manufacture

View more 
Manufacturing Agreement with Bioporto A/S(copy)

Manufacturing Agreement with Bioporto A/S(copy)

York, U.K. 5 July 2021:  Abingdon Health plc (AIM: ABDX) (“Abingdon” or “the Company”), a leading international developer

View more 
Manufacturing Agreement with Bioporto A/S

Manufacturing Agreement with Bioporto A/S

York, U.K. 5 July 2021:  Abingdon Health plc (AIM: ABDX) (“Abingdon” or “the Company”), a leading international developer

View more 
Peer reviewed performance evaluation and self-test user experience of AbC-19™

Peer reviewed performance evaluation and self-test user experience of AbC-19™

York, U.K. 9th July 2021:  Abingdon Health plc (“the Company”), a leading international developer

View more 
AbC-19™ IgG LFD successfully used semi-quantitively to monitor vaccine responses to variant proteins

AbC-19™ IgG LFD successfully used semi-quantitively to monitor vaccine responses to variant proteins

AbC-19TM able to detect different levels of antibody response to the AstraZeneca and Pfizer vaccines as well as those post-infection

View more 
Disclosure of Detailed Grounds for Resistance – Clarification regarding factual inaccuracies in relation to the judicial review proceedings

Disclosure of Detailed Grounds for Resistance – Clarification regarding factual inaccuracies in relation to the judicial review proceedings

York, U.K. 9 August 2021:  Abingdon Health plc (AIM: ABDX), a leading international developer

View more 
Launch of BioSURE COVID-19 IgG Antibody Self Test

Launch of BioSURE COVID-19 IgG Antibody Self Test

Contract manufacturing for CE marked self-test to monitor antibody status Abingdon Health plc (AIM: ABDX)

View more 
Abingdon Health features in ShareBuyers’ Going for Growth Series

Abingdon Health features in ShareBuyers’ Going for Growth Series

Today Abingdon Health's CEO, Chris Yates, spoke with ShareBuyers, an investor

View more 
Launch of Semi-Quantitative Accessory to AbC-19™ – To help indicate the strength of antibody response and possible immunity

Launch of Semi-Quantitative Accessory to AbC-19™ – To help indicate the strength of antibody response and possible immunity

York, U.K. 7 September 2021: Abingdon Health plc (AIM: ABDX), a leading international developer

View more 
Powered by MakeWebEasy.com